Study of ARR-002 for advanced ovarian or endometrial cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant or you can't have standard therapy.
- You have at least one tumor that can be measured on a scan.
- You must provide a tumor sample or agree to a biopsy.
- You are physically able to carry out daily activities (ECOG score 0 or 1).
- Your doctor thinks you have at least 12 weeks to live.
- You must use birth control if you can become pregnant, during and 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests an experimental drug called OPB-201 for people with certain gynecologic cancers (endometrial, ovarian, peritoneal, or fallopian tube) that have come back after treatment. The drug is designed to help your immune system recognize and fight cancer cells that carry a specific marker called PRAME.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.